Survodutide

Dual GLP-1 / glucagon agonist (Boehringer Ingelheim / Zealand) — studied for weight loss and NASH.

Survodutide is another GLP-1/glucagon dual agonist, from Boehringer Ingelheim and Zealand. Its standout feature is what the glucagon arm does to body composition: in the Phase 3 SYNCHRONIZE-1 trial it produced ~16.6% weight loss while preferentially burning fat and sparing lean mass — a benefit pure GLP-1 drugs don't share. It's also a leading candidate for liver disease, with dedicated Phase 3 MASH trials (LIVERAGE) reading out in 2026. Still investigational for now.